GIGA-564 is under clinical development by GigaGen and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how GIGA-564’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GIGA-564 overview
GIGA-564 is under development for the treatment of solid tumor. They act by targeting CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4). The drug candidate is fully human monoclonal antibody with validated cellular activity which are developed based on surge technology. It is administered through intravenous route.
It was also under development for melanoma.
GigaGen overview
GigaGen, a subsidiary of Grifols, is a biotechnology company that develops advancing transformative antibody drugs to treat diseases of immune deficiencies, infectious diseases and checkpoint-resistant cancers. The company pipeline product includes GIGA-564 which is a monoclonal drug candidate which binds the key oncology protein CTLA-4; GIGA-2339 which is a anti-hepatitis B virus recombinant hyperimmune. GigaGen’s single-cell discovery and development platforms capture and recreate the wide range of antibodies found naturally in the human body after an immune response. The company’s novel technology platforms include polyclonal antibody therapies for the treatment of infectious diseases. GigaGen is headquartered in San Francisco, California, the US.
For a complete picture of GIGA-564’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
